Verastem Inc (VSTM) - Total Assets
Based on the latest financial reports, Verastem Inc (VSTM) holds total assets worth $227.81 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Verastem Inc (VSTM) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Verastem Inc - Total Assets Trend (2010–2025)
This chart illustrates how Verastem Inc's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Verastem Inc to see how much of total assets are deployed in long-term investments.
Verastem Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Verastem Inc's total assets of $227.81 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.2% |
| Accounts Receivable | $8.81 Million | 3.6% |
| Inventory | $1.83 Million | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $16.43 Million | 6.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Verastem Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Verastem Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verastem Inc's current assets represent 90.7% of total assets in 2025, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 83.2% of total assets in 2025, down from 99.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 6.7% of total assets.
Verastem Inc Competitors by Total Assets
Key competitors of Verastem Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Verastem Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.04 | 3.50 | 9.01 |
| Quick Ratio | 3.00 | 3.50 | 9.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $136.06 Million | $89.08 Million | $102.02 Million |
Verastem Inc - Advanced Valuation Insights
This section examines the relationship between Verastem Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.14 |
| Latest Market Cap to Assets Ratio | 1.31 |
| Asset Growth Rate (YoY) | 142.7% |
| Total Assets | $246.44 Million |
| Market Capitalization | $322.50 Million USD |
Valuation Analysis
Above Book Valuation: The market values Verastem Inc's assets above their book value (1.31x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Verastem Inc's assets grew by 142.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Verastem Inc (2010–2025)
The table below shows the annual total assets of Verastem Inc from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $246.44 Million | +142.71% |
| 2024-12-31 | $101.54 Million | -32.18% |
| 2023-12-31 | $149.72 Million | +57.51% |
| 2022-12-31 | $95.05 Million | -12.53% |
| 2021-12-31 | $108.66 Million | -29.60% |
| 2020-12-31 | $154.35 Million | +6.41% |
| 2019-12-31 | $145.05 Million | -47.68% |
| 2018-12-31 | $277.24 Million | +208.76% |
| 2017-12-31 | $89.79 Million | +7.37% |
| 2016-12-31 | $83.63 Million | -26.05% |
| 2015-12-31 | $113.09 Million | +14.64% |
| 2014-12-31 | $98.65 Million | -21.25% |
| 2013-12-31 | $125.26 Million | +34.80% |
| 2012-12-31 | $92.92 Million | +57.40% |
| 2011-12-31 | $59.04 Million | +1538.10% |
| 2010-12-31 | $3.60 Million | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more